Stocks Health care TCRX
NASDAQ · Health careTScan Therapeutics, Inc. (TCRX)
TScan Therapeutics, Inc. brought in $7.1M of revenue over the twelve months to June 30, 2026, up 2.2% from a year earlier. It posted a net loss of $117.7M. In fiscal 2025 capital spending exceeded operating cash flow by $139.7M. At June 30, 2026 it held $100.2M in cash against $32.8M of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 12, 2026.
Key facts about TScan Therapeutics, Inc.
- Net worth
- TScan Therapeutics, Inc. has a market value (market cap) of $11.6M at the latest share price, and shareholders' equity of $69M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $10.3M (+266.7% year on year), with a net loss of $129.8M. Over the 12 months to June 30, 2026: revenue $7.1M, net loss $117.7M.
- Cash flow
- In fiscal 2025 operations used $135.3M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 12, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- TScan Therapeutics, Inc.'s next report is expected around November 11, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
What TScan Therapeutics, Inc. does
TScan Therapeutics, Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker TCRX.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $10.3M | -$129.8M | -$1.00 | -$139.7M |
| 2024 | $2.8M | -$127.5M | -$1.14 | -$114.6M |
| 2023 | $21M | -$89.2M | -$1.36 | -$64.5M |
| 2022 | $13.5M | -$66.2M | -$2.75 | -$70.7M |
| 2021 | $10.1M | -$48.6M | -$4.17 | -$58.6M |
| 2021 | $1.1M | -$26.1M | -$28.52 | -$7.3M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where TCRX ranks in Health care
Latest SEC filings
What TScan Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 30, 2026Executive or director change8-KTScan Therapeutics entered into separation agreements with its departing Chief Financial Officer and Chief Medical Officer following a strategic reorganization.
- September 25, 2026Passive stake (5% or more) SCHEDULE 13G
- September 11, 2026
- September 2, 2026
- August 18, 2026
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 12, 2026Quarterly report 10-Q · period to June 30, 2026Revenue fell 66% to $1.1M versus the same quarter last year; diluted EPS -$0.23 versus -$0.28.
- August 12, 2026
- June 22, 2026
Insider trades
What the people running TScan Therapeutics, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider bought or sold shares on the open market in the last 90 days. The 2 reported changes were pay in shares, option exercises, shares withheld for tax or gifts.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| October 1, 2026 | Zdraveski ZoranSee Remarks | Received as pay | 300,000 | - |
| October 1, 2026 | MacBeath GavinChief Executive Officer, Director | Received as pay | 1,000,000 | - |
| December 23, 2025 | Lynx1 Capital Management LP10% owner | Boughtindirect | 6,232 | $5.6K |
| December 22, 2025 | Lynx1 Capital Management LP10% owner | Boughtindirect | 75,500 | $68K |
| December 19, 2025 | Lynx1 Capital Management LP10% owner | Boughtindirect | 80,069 | $72K |
Who owns TCRX
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Lynx1 Capital Management LP13G, passive with 1 related filers | 13.1% | August 14, 2026 |
| Bvf Partners L P13G, passive with 9 related filers | 9.99% | August 14, 2026 |
| K2 HealthVentures Equity Trust LLC13G, passive with 2 related filers | 6.9% | February 14, 2025 |
| Baker Bros. Advisors LP13D, may seek influence with 3 related filers | 6.1% | April 23, 2024 |
| Readout Capital, LP13G, passive with 2 related filers | 5.4% | September 25, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 60 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Lynx1 Capital Management LP | 8,019,148 | 0 |
| Bvf Inc | 5,564,290 | 0 |
| Baker Bros. Advisors LP | 2,784,792 | 0 |
| Vanguard Capital Management LLC | 2,158,831 | +4,575 |
| Two Sigma Investments, LP | 1,949,604 | +740,595 |
| Renaissance Technologies LLC | 1,326,799 | -37,984 |
| Deer Management Co. LLC | 1,245,504 | 0 |
| Millennium Management LLC | 1,163,611 | -296,674 |
| Jacobs Levy Equity Management, Inc | 1,049,806 | +241,450 |
| Citadel Advisors LLC | 1,009,107 | +690,696 |
| BlackRock, Inc. | 994,654 | -846,298 |
| Kalehua Capital Management LLC | 909,752 | new |
| Boothbay Fund Management, LLC | 772,241 | new |
| Marshall Wace, Llp | 687,364 | +450,018 |
| DC Funds, LP | 630,000 | 0 |
| Geode Capital Management, LLC | 584,811 | -32,141 |
| D. E. Shaw & Co., Inc. | 548,402 | +228,815 |
| Vanguard Fiduciary Trust Co | 363,954 | +58,182 |
| Jane Street Group, LLC | 241,493 | +97,072 |
| Verdad Advisers, LP | 232,759 | +98,758 |
Insiders
3 insiders reported holding 17,311,047 shares in total, about $3.2M at the last price.
| Holder | Shares |
|---|---|
| Lynx1 Capital Management LP10% owner | 15,956,56415,956,564 held indirectly |
| MacBeath GavinChief Executive Officer, Director | 1,049,767 |
| Zdraveski ZoranSee Remarks | 304,716 |
Questions about TCRX
What does TScan Therapeutics, Inc. do?
TScan Therapeutics, Inc. is a company in the Health care sector, listed on NASDAQ as TCRX. Its shares trade on NASDAQ under the ticker TCRX.
What is TScan Therapeutics, Inc.'s net worth?
TScan Therapeutics, Inc. has a market value (market cap) of $11.6M at the latest share price, and shareholders' equity of $69M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is TScan Therapeutics, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $117.7M on revenue of $7.1M.
How much revenue does TScan Therapeutics, Inc. make?
Over the twelve months to June 30, 2026 TScan Therapeutics, Inc. reported revenue of $7.1M. That is 2.2% more than a year earlier.
When did TScan Therapeutics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 12, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the insider trade from October 2, 2026.
When is TScan Therapeutics, Inc.'s next earnings report?
TScan Therapeutics, Inc.'s next report is expected around November 11, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare TCRX with
Follow TCRX
Get an email when TScan Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values TScan Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.